News

SNBL Client CytoDyn Files IND for Respiratory Complications Therapy due to COVID-19

Tokyo, Japan March 12, 2020  A client of Shin Nippon Biomedical Laboratories, Ltd. (hereafter, SNBL), CytoDyn Inc. (Vancouver, Washington, USA, hereafter CytoDyn) has filed an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) in order to conduct a Phase 2 clinical trial using leronlimab (PRO 140) as a therapy for patients who have respiratory complications as a result of the novel coronavirus disease 2019 (COVID-19). COVID-19 is the respiratory disease that may result from contraction of SARS-CoV-2, which was recently declared a global pandemic by the World Health Organization (WHO). Researchers all over the world are working on therapeutic pharmaceuticals to treat COVID-19, and SNBL would like to introduce CytoDyn’s therapy.

Although COVID-19 has spread throughout the world and is a threat to both individuals and to society, research and development of therapeutics is progressing at a rapid pace around the world, including at CytoDyn. SNBL Group’s mission is to free patients from suffering, by supporting drug development and improving medical technology, and we sincerely hope that that therapeutic drugs will reach patients as soon as possible. SNBL contributes to that mission by working with clients such as CytoDyn.

 

About Leronlimab and COVID-19

According to CytoDyn’s press release on March 9, 2020, their trial using leronlimab will focus on patients that develop mild-to-moderate respiratory illness after transmission of COVID-19.

CytoDyn president and Chief Executive Officer Nader Pourhassan, Ph.D. states that “we believe leronlimab could reduce the inflammation which contributes to Acute Respiratory Distress Syndrome (ARDS).” The migration into areas of inflammation of tregs, which can inhibit the innate immune response against pathogens, can be mitigated by Leronlimab.  The serious damage in the lungs exhibited by some patients is caused by migration of macrophages and the release of inflammatory cytokines including TNF and IL-6 (called a cytokine storm). 

 

About Leronlimab

The US FDA have granted CytoDyn a “Fast Track” designation for two potential indications of leronlimab; for HIV as a combination therapy with HAART and for metastatic triple-negative breast cancer.  In late 2019, CytoDyn announced that they signed agreements to commercialize leronlimab after securing manufacturing contracts. Leronlimab masks a cellular receptor that is important in HIV infection

Leronlimab’s target is CCR5, a cellular receptor that is immunologically important. The CCR5 receptor is a protein located on the surface of various cells, including leukocytes and cancer cells. On leukocytes, they act as receptors for chemoattractants called chemokines. The CCR5 receptor is also required for HIV to infect healthy T cells. Recent studies identified the CCR5 receptor as an important target for many disease processes, including cancer metastasis and certain immunological conditions.

Leronlimab is a unique humanized monoclonal antibody that belongs to a new class of HIV / AIDS treatments that prevents HIV from using the CCR5 receptor as an entry gateway for healthy cells and protects healthy cells from viral infections, in comparison with HAART, the current standard of care for HIV, which allows the virus to enter the cell and start replicating before it can attack the virus. Other benefits of leronlimab include an improved safety profile, longer half-life, and reduced dosing frequency.

 

About CytoDyn

CytoDyn is a biotechnology company focused on developing innovative treatments for multiple therapeutic indications. Their lead candidate compound, leronlimab, belongs to a new class of therapeutics called viral entry inhibitors, and is one of the most advanced experimental monoclonal antibodies for the treatment of HIV.

 

About SNBL

Shin Nippon Biomedical Laboratories, Ltd. (hereafter, SNBL) is a preclinical contract research organization (CRO) that was founded in Kagoshima, Japan in 1957. SNBL’s mission is to free patients from suffering, by supporting drug development and improving medical technology, and has focused since its founding on the preclinical studies necessary for the development of pharmaceuticals, medical devices, and products such as regenerative medicine. Preclinical safety studies in drug development are conducted to clarify the characteristics of new drug candidate compounds and their in vivo effects with reliable data. SNBL’s strength is conducting preclinical safety and efficacy studies, and pharmaceutical companies, biotech ventures, universities and research institutions trust SNBL to provide the data they need for their invaluable research.

 

 

SNBL at ACT2019

 

 SNBL will be exhibiting at the American College of Toxicology from November 17 to 20, 2019. If you are at ACT please pop by Booth #103 and let's chat about how we can support your drug development program. 

 

SNBL to be represented by Medgaea Life Sciences, Ltd. in Taiwan

 SNBL and Medgaea Life Sciences, Ltd. (MDG) have signed an agreement for Medgaea Life Sciences to represent SNBL in Taiwan.

 

The pharmaceutical industry is growing in Taiwan with government support, concentrated around biopharmaceuticals. With its close location and commitment to quality, SNBL is a great choice for preclinical contract research for Taiwanese organizations.

 

MDG was established in Taiwan in 2005 and offers a variety of preclinical contract research services for medical devices, health foods, pharmaceuticals, and herbal remedies. SNBL and MDG have an excellent cooperative relationship.

 

The partnership between SNBL and MDG will offer an abundance of support for R&D of pharmaceuticals, medical devices, and regenerative medicine in Taiwan.

 

 

Presenting at the Safety Pharmacology Society in Barcelona

At the Safety Pharmacology Society 2019, held in Barcelona from September 23-26, Tsuyoshi Uchino, who is one of SNBL's safety pharmacology experts will present a poster entitled "Utility of Heart Rate Variability Analysis in Telemeterized Cynomolgus Monkeys" on September 24 and 25. 

 

If you are attending SPS, please visit Tsuyoshi at Poster #134.

 

Otherwise please email info@snbl.co.jp if you are interested in obtaining a copy of the poster.

Gemseki chosen as Top 10 by magazine

Gemseki, a member of SNBL group, was chosen as one of the top 10 drug discovery service companies in APAC by Pharma Tech Outlook, and is the cover story for the the Safety Pharmacology Society 2019.

 

See a PDF link to the media release here.

 

 

Meet SNBL at Eurotox 2019

 

 

 

 

SNBL will be exhibiting at the 55th Eurotox Congress from 8 - 11 September in Helsinki, Finland.

 

Drop by Booth #61 or email info@snbl.co.jp to see how SNBL can provide preclinical support for your drug development program.

 

 

 

 

 

 

0 Comments

Come visit us at the International Congress of Toxicology

 

 

 

 

Join SNBL from July 15 to 18 in Honolulu for the 15th International Congress of Toxicology. Drop by Booth 401 or email info@snbl.co.jp to see how SNBL can provide preclinical support for your drug development program.

 

 

 

 

 

 

Come visit us at the Teratology Society Meeting 2019

 

 

 

SNBL is known for its high quality developmental and reproductive preclinical studies, and we would be happy to discuss how we can help your drug development program at the annual Teratology Society Meeting in San Diego this June. Email info@snbl.co.jp to make an appointment or visit Booth #4.

 

 

 

 

 

Come visit us at BIO 2019

 

 

 

 

Are you attending BIO 2019 in Philadelphia June 3-6? SNBL will be at the JETRO booth #1509, and we would be happy to discuss how our preclinical safety testing can support your drug development program. Email info@snbl.co.jp to make an appointment.

 

 

 

 

 

Come visit us at ARVO 2019

 

 

 

 SNBL will be exhibiting at ARVO, The Association for Research in Vision and Ophthalmology, to be held in Vancouver from April 28 to May 2. We will be at Booth #1643 to introduce our new capability of OCT angiography for preclinical evaluation. Email us at info@snbl.co.jp to set up a meeting.

 

 

 

 

 

Honorable Mention at the 35th Scientific Meeting of JSTP

One of our pathologists at SNBL, Haruno Yabuki, DVM, received the top honorable mention for a poster she presented at the 35th Scientific Meeting of the Japanese Society of Toxicologic Pathology (JSTP). This meeting is a gathering of nearly all toxicologic pathologists in Japan, whether from pharmaceutical companies or CROs, educational institutions, or public research institutions, and was a great opportunity to show SNBL’s high level of scientific quality.

 

 

Congratulations Dr. Yabuki!

 

 

Health & Productivity Award 2019

For the third year in a row, SNBL Japan received the Health & Productivity Award, presented by the Japanese Ministry of Economy, Trade and Industry. This award recognizes organizations which promote health in their region by implementing strategies to improve the health and productivity of their employees.

 

As part of its strategy to improve employee health, SNBL Japan has implemented Wellness Tourism seminars, a series of health challenges, and early cancer screenings. SNBL Japan will strive to continue these efforts and ensure that the recognition of our strategy is meaningful.